Collegium Pharmaceutical (COLL) Gains from Sales and Divestitures (2015 - 2025)

Collegium Pharmaceutical's Gains from Sales and Divestitures history runs 11 years deep, the most recent figure standing at $980992.0 for Q3 2025.

• In Q3 2025, Gains from Sales and Divestitures rose 4.32% year-over-year to $980992.0; the TTM figure through Sep 2025 stood at $980992.0 (up 4.32% YoY), while the FY2024 annual figure was $514050.0, down 23.92% from the prior year.
• Gains from Sales and Divestitures was $980992.0 for Q3 2025 at Collegium Pharmaceutical, up from $895705.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $980992.0 in Q3 2025 to a low of $66974.0 in Q2 2021.
• Historically, Gains from Sales and Divestitures has averaged $396200.0 across 5 years, with a median of $223170.0 in 2023.
• The sharpest annual moves came in 2021 and 2022: Gains from Sales and Divestitures slumped 80.04% in 2021, then surged 755.86% in 2022.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $66974.0 in 2021, then surged by 755.86% to $573204.0 in 2022, then increased by 17.87% to $675647.0 in 2023, then decreased by 23.92% to $514050.0 in 2024, then soared by 90.84% to $980992.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $980992.0 (Q3 2025), $895705.0 (Q2 2025), and $163423.0 (Q1 2025), per Business Quant data.